Novel Serum Markers for the Diagnosis of Concussions and Mild Traumatic Brain Injury (HDL particles size and with combination with S100B)


This invention offers novel serum markers that can be used to diagnose mild traumatic brain injury (mTBI) in a time- and cost-efficient fashion. Traumatic brain injury (TBI) affects over one million patients each year in the United States. Nearly 90% of these injuries are classified as mTBI or concussion, which leads to subtle cognitive dysfunction. Diagnosis of mTBI relies on a clinical history alone. Reliable objective aids for the diagnosis are currently unavailable. Disclosed here are proprietary biomarkers whose serum concentrations are substantially decreased within 6 hours of mTBI, but not affected by extracranial trauma. As such, the simple biomarker test would have substantial utility in military populations in war zones, athletes in competitive sports as well as in civilians presenting to emergency departments. 



Current diagnosis of mTBI requires an accurate clinical history.  However, confounding factors such as conditions mimicking TBI like syncope, intoxication, or seizures complicate clinical diagnosis. Willful misreporting of symptoms is also a significant problem particularly with athletes and military personnel. An objective test would circumvent these problems. The novel biomarkers covered here have the characteristics required for such a test and has the further advantage of not being affected by trauma without TBI.  

URV Reference Number: 6-1897
Patent Information:
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
Bryan Blyth
Jeffrey Bazarian